Retatrutide beats Ozempic on weight and A1C in Lilly's head-to-head trial

Eli Lilly's experimental drug retatrutide helped adults with type 2 diabetes lose more than twice as much weight as Ozempic, and lowered their blood sugar further, in the first head-to-head trial between the two, the company said on October 28, 2026. In the phase 3 TRANSCEND-T2D-2 study of 1,298 adults, people on retatrutide lost an average of 20% to 21% of their body weight over 80 weeks, against 9% for those on the highest approved dose of Ozempic, 2 mg. The trial results, the topic behind searches for "Ozempic versus retatrutide A1C study", come from Lilly's own announcement; the full data have not yet been published in a journal. Retatrutide is not approved anywhere, and Lilly says it plans to apply to the US Food and Drug Administration in early 2027.

Ozempic, made by Novo Nordisk, is a semaglutide injection that copies one gut hormone, GLP-1, which tells the brain the body is full and helps the pancreas release insulin. It has become one of the best-known medicines in the world, used for diabetes and, in a related form, for weight loss. Retatrutide works on three hormone signals at once: GLP-1, GIP and glucagon. That is why it is sometimes called a "triple agonist". The idea is that acting on three signals together gives a stronger effect than acting on one.

Until now, comparisons between retatrutide and Ozempic were made across separate studies, which can mislead because the people and the trial designs differ. This trial put them side by side in the same group of patients, which makes the result much stronger. Both a bigger fall in blood sugar and more than double the weight loss matter for people with type 2 diabetes, because excess weight makes the disease harder to control and raises the risk of heart and kidney problems.

The trade-off is side effects. More people on retatrutide stopped treatment because of them, particularly at the higher dose. Stomach problems were the most common, and Lilly said most of these events were mild to moderate. Lilly also reported dysesthesia, an unusual or unpleasant skin sensation, more often with retatrutide than with Ozempic. Doctors will want to see the full, peer-reviewed data before judging the balance.

Short-term: Nothing changes for patients yet, because retatrutide is still experimental. The results will raise interest among doctors and patients, and roughly 650 participants are continuing on retatrutide for another 24 weeks to test long-term safety and effect.

Long-term: If regulators approve it, retatrutide could become one of the strongest medicines available for type 2 diabetes with obesity, adding to competition with Novo Nordisk's drugs and other newer medicines. Price and supply will decide how many people can use it, especially in countries like India, where diabetes is common.

Who is affected: People living with type 2 diabetes and obesity, many of them women managing weight, blood sugar and family responsibilities at once; their doctors; and drug makers competing in the fast-growing market for these medicines.

Questions and Answers